MaxQ AI
The Nuance AI Marketplace for Diagnostic Imaging brings our revolutionary AI-powered ICH detection solutions to radiologists across the globe in their preferred workflow, said Gene Saragnese, CEO of MaxQ AI
TEL AVIV, Israel (PRWEB)
October 23, 2019
MaxQ AI, the industry-leading medical diagnostic AI company, today announced that its Accipio Ix™ and Accipio Ax™ intracranial hemorrhage (ICH) detection software will be available on the Nuance® AI Marketplace, the first and largest portal with one-stop access to a wide range of AI diagnostic models from within the industry’s most widely used radiology reporting platform.
MaxQ AI’s ACCIPIO® ICH and Stroke Platform utilizes deep learning technologies to analyze medical imaging data such as non-contrast head CT images. The results provide deep clinical insight and actionable data in minutes that will enable physicians across the world to make faster assessments of stroke, traumatic brain injury, and head trauma in any location, at any time. Accipio Ix enables automatic identification and prioritization of non-contrast head CT images with suspected ICH. Accipio Ax provides automatic slice-level annotation of suspected ICH. Both Accipio Ix and Ax are FDA Cleared and CE Approved.
The Nuance AI Marketplace functions like an app store dedicated to radiology. It gives algorithm developers consolidated, at-scale access to users of Nuance PowerScribe™, the radiology reporting system trusted by approximately 3 out of 4 U.S. radiologists across more than 6,500 connected healthcare facilities. Radiologists can discover, test, and use algorithms from within their familiar PowerScribe workflows to increase reporting efficiency and quality and to help care teams improve patient outcomes and healthcare costs. A built-in feedback channel lets users share real-world results with developers for algorithm refinement and post-market surveillance. Hospital systems benefit with simplified purchasing and metrics showing algorithm usage, costs, and performance.
“The Nuance AI Marketplace for Diagnostic Imaging brings our revolutionary AI-powered ICH detection solutions to radiologists across the globe in their preferred workflow,” said Gene Saragnese, CEO of MaxQ AI. “This availability of our Accipio ICH detection, stroke, and head trauma solutions through Nuance’s cloud-based marketplace will support potential diagnostic improvements, which will improve patient outcomes and lower healthcare costs. This will fuel the best possible care in all market segments by bringing near real-time clinical decision support to care teams.”
MaxQ AI will demonstrate the company’s full suite of Accipio solutions during the upcoming Radiological Society of North America (RSNA) 2019 Annual Meeting in Chicago (Booth 8345 in the North Hall). Accipio also will be on display as part of the Nuance AI Marketplace at Nuance’s main exhibit (Booth 3300 in the South Hall) and in the AI Showcase (Booth 11410B in the North Hall Level 2).
About MaxQ AI, Ltd.
MaxQ AI is at the forefront of Medical Diagnostic AI. We are transforming healthcare by empowering physicians to provide “smarter care” with artificial intelligence (AI) clinical insights. Based in Tel Aviv, Israel and Andover, MA, USA, our team of deep learning and machine vision experts develop innovative software that uses AI to interpret medical images and surrounding patient data. Working with world-class clinical and industry partners, our software enables physicians to make faster, more accurate decisions when diagnosing stroke, traumatic brain injury and other serious conditions. To learn more, visit http://www.maxq.ai or follow us on Twitter and LinkedIn.
Share article on social media or email: